215 related articles for article (PubMed ID: 27267988)
1. Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer.
Beauval JB; Roumiguié M; Filleron T; Benoit T; de la Taille A; Malavaud B; Salomon L; Soulié M; Ploussard G
BMC Urol; 2016 Jun; 16(1):26. PubMed ID: 27267988
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
3. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?
Klaassen Z; Singh AA; Howard LE; Feng Z; Trock B; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Kane CJ; Partin A; Han M; Freedland SJ
Cancer; 2015 May; 121(9):1414-21. PubMed ID: 25492369
[TBL] [Abstract][Full Text] [Related]
4. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
[TBL] [Abstract][Full Text] [Related]
6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
[TBL] [Abstract][Full Text] [Related]
8. Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy.
Pagano MJ; Whalen MJ; Paulucci DJ; Reddy BN; Matulay JT; Rothberg M; Scarberry K; Patel T; Shapiro EY; RoyChoudhury A; McKiernan J; Benson MC; Badani KK
Prostate; 2016 Feb; 76(2):226-34. PubMed ID: 26481325
[TBL] [Abstract][Full Text] [Related]
9. Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes.
Imnadze M; Sjoberg DD; Vickers AJ
Eur Urol; 2016 Jan; 69(1):143-8. PubMed ID: 25913389
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
[TBL] [Abstract][Full Text] [Related]
11. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
12. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series.
Gandaglia G; Ploussard G; Isbarn H; Suardi N; De Visschere PJ; Futterer JJ; Ghadjar P; Massard C; Ost P; Sooriakumaran P; Surcel CI; van der Bergh RC; Montorsi F; Ficarra V; Giannarini G; Briganti A;
Urol Oncol; 2015 Apr; 33(4):164.e1-9. PubMed ID: 25620154
[TBL] [Abstract][Full Text] [Related]
13. Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.
Hamada R; Nakashima J; Ohori M; Ohno Y; Komori O; Yoshioka K; Tachibana M
Int J Clin Oncol; 2016 Jun; 21(3):595-600. PubMed ID: 26585896
[TBL] [Abstract][Full Text] [Related]
14. Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence rates.
Mandel P; Oh SJ; Hagner C; Tennstedt P; Kriegmair MC; Huland H; Graefen M; Tilki D
World J Urol; 2016 Nov; 34(11):1547-1553. PubMed ID: 27003277
[TBL] [Abstract][Full Text] [Related]
15. Preoperative Predictors of Biochemical Recurrence-Free Survival in High-Risk Prostate Cancer Following Radical Prostatectomy.
Nkengurutse G; Tian F; Jiang S; Wang Q; Wang Y; Sun W
Front Oncol; 2020; 10():1761. PubMed ID: 33014867
[No Abstract] [Full Text] [Related]
16. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.
Ploussard G; Masson-Lecomte A; Beauval JB; Ouzzane A; Bonniol R; Buge F; Fadli S; Rouprêt M; Rebillard X; Gaschignard N; Pfister C; Villers A; Soulié M; Salomon L;
Urology; 2011 Sep; 78(3):607-13. PubMed ID: 21783233
[TBL] [Abstract][Full Text] [Related]
17. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification system and pattern of relapse in patients treated with adjuvant radiotherapy after radical prostatectomy.
Levis M; Guarneri A; Giaj Levra N; Spratt DE; Bartoncini S; Munoz F; Trino E; Botticella A; Arcadipane F; Ricardi U
Tumori; 2016 Jun; 2016(3):323-9. PubMed ID: 27002951
[TBL] [Abstract][Full Text] [Related]
19. Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram.
Abdollah F; Klett DE; Sood A; Sammon JD; Pucheril D; Dalela D; Diaz M; Peabody JO; Trinh QD; Menon M
BJU Int; 2015 Nov; 116(5):703-12. PubMed ID: 25413443
[TBL] [Abstract][Full Text] [Related]
20. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]